Sun Pharmaceutical Industries has launched its plaque psoriasis treatment drug ‘ILUMYA’ (tildrakizumab-asmn) 100 mg/mL in the United States. ILUMYA is an injectable interleukin-23 (IL-23) inhibitor approved by the USFDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
